Wang Yufei, Li Guangliang, Wang Hanying, Qi Quan, Wang Xian, Lu Haiqi
Department of Medical Oncology, Sir Run Run Shaw Hospital, Medical School of Zhejiang University, Hangzhou, China; Laboratory of Cancer Biology, Key Lab of Biotherapy in Zhejiang, Sir Run Run Shaw Hospital, Medical School of Zhejiang University, Hangzhou, China.
Department of Medical Oncology (Breast Cancer), Zhejiang Cancer Hospital, Hangzhou, China.
Breast. 2025 Feb;79:103838. doi: 10.1016/j.breast.2024.103838. Epub 2024 Nov 14.
Nectin-4 is a cell adhesion molecule which has gained more and more attention as a therapeutic target in cancer recently. Overexpression of Nectin-4 has been observed in various tumors, including breast cancer, and is associated with tumor progression. Enfortumab vedotin(EV)is an antibody-drug conjugate (ADC) targeting Nectin-4, which has been approved by FDA for the treatment of urothelial carcinoma. Notably, Nectin-4 was also investigated as a target for breast cancer in preclinical and clinical settings. Nectin-4-targeted approaches, such as ADCs, oncolytic viruses, photothermal therapy and immunotherapy, have shown promising results in early-phase clinical trials. These therapies offer novel strategies for delivering targeted treatments to Nectin-4-expressing cancer cells, enhancing treatment efficacy and minimizing off-target effects. In conclusion, this review aims to provide an overview of the latest advances in understanding the role of Nectin-4 in breast cancer and discuss the future development prospects of Nectin-4 targeted agents.
Nectin-4是一种细胞粘附分子，最近作为癌症治疗靶点受到越来越多的关注。在包括乳腺癌在内的各种肿瘤中均观察到Nectin-4的过表达，且其与肿瘤进展相关。恩沃利单抗（EV）是一种靶向Nectin-4的抗体药物偶联物（ADC），已获美国食品药品监督管理局（FDA）批准用于治疗尿路上皮癌。值得注意的是，在临床前和临床研究中，Nectin-4也被作为乳腺癌的一个靶点进行研究。以Nectin-4为靶点的方法，如ADC、溶瘤病毒、光热疗法和免疫疗法，在早期临床试验中已显示出有前景的结果。这些疗法为向表达Nectin-4的癌细胞提供靶向治疗、提高治疗效果并将脱靶效应降至最低提供了新策略。总之，本综述旨在概述Nectin-4在乳腺癌中作用的最新研究进展，并探讨Nectin-4靶向药物的未来发展前景。
